| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Revenue | $0 | — |
| R&D Expense | $25.2M | +26.1% |
| SG&A Expense | $4.5M | -33.1% |
| Operating Income | -$29.7M | -11.2% |
| Income Tax | $0 | — |
| Net Income | -$28.9M | -17.3% |
| EPS (Basic) | -$1.40 | +30.7% |
| EPS (Diluted) | -$1.40 | +39.4% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $19.5M | +85.1% |
| Total Assets | $21.1M | +51.4% |
| Current Liabilities | $3.6M | -6.3% |
| Total Liabilities | $4.2M | -8.4% |
| Stockholders' Equity | $16.9M | +81.0% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$25.6M | -17.0% |
| Financing Cash Flow | $34.6M | +29.6% |